Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by inspecthrgadgeton May 19, 2021 8:11pm
131 Views
Post# 33235304

RE:Sepsis Stats - Part 2

RE:Sepsis Stats - Part 2

Longs always appreciate your calculations and your understanding of the numbers and ability to explain them in an easy to understand way. 

Ctso and Sigy have advertised the opportunity as being 20 billion. More than 4 billion sounds good enough for me. It is the 1/3 of the severe sepsis patients that I am most interested in. As per former European Critical Care president Dr. Antonelli, he has stated that 1/3 of the severely septic have NO culturable bacteria. This in my opinion is the low hanging fruit we appear reluctant to pick. Im nit worried about it rotting, too many stand to benefit from the harvest. Dr. Antonelli was a key figure in the Euphas phase 2 trial and is also set to soeak in 8 days about PMX at a key European conference. Dr Ronco will also present PMX data as it relates to cv19. Stick with folks, paying close attention allows the Spectral  3D puzzle to form a picture that looks like this...$. Imho and always do your own due diligence!

Best,
Gadge

<< Previous
Bullboard Posts
Next >>